H929-60 cells are not resistant to standard myeloma therapies
| Compound | H929 IC50 (n = 3) | H929-60 IC50 (n = 3) |
|---|---|---|
| Melphalan | 11.3 ± 2.5 μmol/L | 13.1 ± 3.7 μmol/L |
| Mitoxantrone | 1.42 ± 0.4 μmol/L | 1.05 ± 0.7 μmol/L |
| Bortezomib | 11.3 ± 5.1 nmol/L | 12.2 ± 3.9 nmol/L |
NOTE: H929 and H929-60 cells were treated with increasing concentrations of melphalan, mitoxanthrone, or bortezomib for 24 hours. After 24 hours, cells were stained with annexin V–fluorescein isothiocyanate/propidium iodide for 45 minutes and acquired on FACScan. IC50 values were determined by linear regressions. Shown is the mean and SDs of 3 independent experiments.